UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): August 16, 2018
BIO-PATH HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-36333 | 87-0652870 |
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
4710 Bellaire Boulevard, Suite 210, Bellaire, Texas | 77401 |
(Address of principal executive offices) | (Zip Code) |
(832) 742-1357
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01 | Regulation FD Disclosure. |
On August 16, 2018, Bio-Path Holdings, Inc. (the “Company”) issued a press release titled, “Bio-Path Holdings Appoints Dr. Jason B. Fleming to Scientific Advisory Board.” A copy of such press release is attached hereto as Exhibit 99.1.
Item 9.01 | Financial Statements and Exhibits. |
(d) | Exhibits. |
Exhibit
Number | Description |
99.1 | Press Release dated August 16, 2018 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BIO-PATH HOLDINGS, Inc. | ||
Dated: August 16, 2018 | By: | /s/ Peter H. Nielsen |
Peter H. Nielsen President and Chief Executive Officer |
EXHIBIT INDEX
Exhibit
Number | Description |
99.1 | Press Release dated August 16, 2018 |
Exhibit 99.1
Bio-Path Holdings Appoints Dr. Jason B. Fleming to Scientific Advisory Board
HOUSTON — August 16, 2018 – Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the appointment of Jason B. Fleming, M.D., F.A.C.S., to its Scientific Advisory Board (SAB).
“We are thrilled to welcome Dr. Fleming to our scientific advisory board. As a leader in the treatment of gastrointestinal cancers, Dr. Fleming will be able to offer substantial insight as we seek to advance our lead drug candidate prexigebersen and our third drug candidate, BP1003, towards the clinic for the treatment of pancreatic cancer,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path.
“As a surgeon, I am committed to improving treatment options for patients with unmet medical need. I am particularly excited by Bio-Path’s innovative drug candidates that have demonstrated the potential to transform the treatment of pancreatic cancer. I look forward to working with my new colleagues to help advance DNAbilize™ and offer meaningful new treatments for patients,” commented Dr. Fleming.
Dr. Fleming is the Chair and Program Director of the Department of Gastrointestinal Oncology at Moffitt Cancer Center. Prior to joining Moffitt, Dr. Fleming was a professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center, where he served as Chief of Pancreas Surgery and Executive Director of Perioperative Services. In addition to these responsibilities, Dr. Fleming developed a novel patient-derived preclinical tumor model in which he tested new drug candidates for the treatment of pancreatic cancer. Preclinical testing in Dr. Fleming’s model have shown both prexigebersen and BP1003 to successfully penetrate pancreatic tumors and to significantly enhance the efficacy of standard frontline treatments. Bio-Path intends to include pancreatic cancer tumors in the Phase 1 clinical trial of prexigebersen solid tumors which is expected to initiate before the end of 2018.
Dr. Fleming received his M.D. from the University of Tennessee Center of Health Science. He completed his clinical residency in general surgery at the University of Texas Southwestern Medical Center. Dr. Fleming also completed a fellowship at the University of Texas Southwestern Medical Center and a clinical fellowship in surgical oncology at the University of Texas MD Anderson Cancer Center.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and in preclinical studies for solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, which the company anticipates entering into clinical studies where it will be evaluated in lymphoma and solid tumors.
For more information, please visit the Company's website at http://www.biopathholdings.com.
# # #
Contact Information:
Investors
Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
will@sternir.com
Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369
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end